GSK beats Teva on Zofran; Dr. Reddy's case pending
On August 23, 2004, GlaxoSmithKline Plc stated that the U.S. district court in Delaware (Judge Gregory Sleet) had ruled in its favour in patent litigation with Israel's Teva Pharmaceuticals over anti-nausea drug Zofran.
Zofran, used to counteract nausea in cancer patients undergoing chemotherapy, is one of GSK's more important products and had sales of $327 million in the first quarter of 2004.
GSK still awaits a court decision in the district court of New Jersey on whether Indian generic drugmaker Dr. Reddy's Laboratories Ltd can make Zofran pursuant to the Hatch-Waxman Act. The closing arguments in NJ are expected in the next couple of months. One wonders why the two Zofran cases were not combined.
Zofran, used to counteract nausea in cancer patients undergoing chemotherapy, is one of GSK's more important products and had sales of $327 million in the first quarter of 2004.
GSK still awaits a court decision in the district court of New Jersey on whether Indian generic drugmaker Dr. Reddy's Laboratories Ltd can make Zofran pursuant to the Hatch-Waxman Act. The closing arguments in NJ are expected in the next couple of months. One wonders why the two Zofran cases were not combined.
posted by Lawrence B. Ebert at 11:34 PM
0 Comments:
Post a Comment
<< Home